Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34531
Abstract: Patients with metastatic colorectal cancer (mCRC) have poor long-term survival. Rechallenge with anti-epidermal growth factor receptor (anti-EGFR) based therapy has shown certain activity as late-line therapy. To further improve clinical outcomes, we evaluated the antitumor… read more here.
Keywords: cetuximab; metastatic colorectal; liposomal irinotecan; camrelizumab liposomal ... See more keywords
Camrelizumab: an investigational agent for hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2022.2022121
Abstract: INTRODUCTION : Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits were limited, particularly for advanced HCC. However, recent treatments with PD-1/PD-L1 inhibitor monotherapy and its combination with other therapies,… read more here.
Keywords: hepatocellular carcinoma; camrelizumab investigational; camrelizumab; investigational agent ... See more keywords
Comment on “Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma”
Sign Up to like & getrecommendations! Published in 2022 at "Contact Dermatitis"
DOI: 10.1111/cod.14179
Abstract: To the Editor, We read with great interest the article ‘Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma’ by Peng et al., presenting a case of a man who developed toxic epidermal… read more here.
Keywords: anti ssa; anti pd1; ssa antibody; camrelizumab ... See more keywords
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004656
Abstract: Objective This study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy. Methods Initially, 20 patients with HCC were screened and 18 patients… read more here.
Keywords: camrelizumab plus; therapy; plus apatinib; efficacy ... See more keywords
Abstract P1-06-01: Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p1-06-01
Abstract: Background: Triple-negative breast cancer (TNBC) has an aggressive clinical course with a high recurrence rate and risk of metastasis. Camrelizumab, a humanized monoclonal anti-PD-1 antibody, has shown promising prognostic outcomes for patients with TNBC by… read more here.
Keywords: cancer; breast cancer; meta analysis; review ... See more keywords
Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial
Sign Up to like & getrecommendations! Published in 2025 at "BMC Medicine"
DOI: 10.1186/s12916-025-04416-0
Abstract: Camrelizumab (an anti-programmed cell death protein-1 antibody) combined with apatinib (an antiangiogenic agent) has conferred benefits for advanced NSCLC. This study aimed to assess the efficacy and safety of camrelizumab and apatinib alongside chemotherapy in… read more here.
Keywords: iiia nsclc; camrelizumab apatinib; rate; camrelizumab ... See more keywords
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0636-7
Abstract: Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking.… read more here.
Keywords: chemotherapy; safety; efficacy; camrelizumab ... See more keywords
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.tps4193
Abstract: TPS4193 Background: The combination of anti-angiogenesis and immune checkpoint blockade showed promising outcomes for advanced hepatocellular carcinoma (HCC). Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab could augment treatment efficacy in preliminary study.… read more here.
Keywords: camrelizumab; trial; infusion; apatinib camrelizumab ... See more keywords
Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.2597
Abstract: 2597 Background: Definitive concurrent chemoradiotherapy (dCCRT) is considered the standard treatment for esophageal squamous cell carcinoma (ESCC). The PACIFIC study demonstrated that consolidation durvalumab significantly improves overall survival (OS) in patients with stage III non-small… read more here.
Keywords: camrelizumab; locally advanced; cell; concurrent chemoradiotherapy ... See more keywords
Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.445
Abstract: 445 Background: Camrelizumab in combination with chemotherapy has become a standard of care for the first-line treatment of advanced ESCC. Previous studies have indicated synergistic effect of fruquintinib in combination with chemotherapy or immunotherapy. Hence,… read more here.
Keywords: treatment; camrelizumab; fruquintinib; first line ... See more keywords
Use of immune repertoire sequencing analysis to detect differences in treatment responses for advanced esophageal squamous cell carcinoma treated with camrelizumab and platinum-based chemotherapy.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.488
Abstract: 488 Background: The study evaluated the efficacy and safety of camrelizumab combined with platinum-based chemotherapy (platinum plus paclitaxel [TP] or fluorouracil [FP] agents) as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC),… read more here.
Keywords: year; treatment; rate; camrelizumab ... See more keywords